A bad week for statins
Despite the fact that statin drugs are the best-selling medications in history, accounting for some $40 billion plus in sales world wide last year, they had a very bad week this past week. And it looks like their scrutiny is going to pick up a little.
The Vytorin trial that finally came to light late last week kicked off the cascade of bad news. It appears that the combination of a statin and Zetia, despite lowering cholesterol levels by 40 percent more than a statin, was no more effective than the statin alone in preventing problems. Which would lead anyone with critical thinking skills to wonder about the hypothesis that LDL-cholesterol is really a problem.
The next day the New York Times, in an article that wasn’t all that anti-statin, started thusly: Read more »
Hello! This is Dr. Mike - If you're new here and you've enjoyed my posts, you may want to subscribe to my RSS feed. Thanks for visiting!







